Clinical Trials
1015 South Mercer Avenue  ●  Bloomington, Illinois 61701  ●  Toll Free 800.997-CINF  ●  Telephone 309.663.1522  ●  Facsimile 309.663.2344
The Central Illinois Neuroscience Foundation promotes, supports and encourages clinical research in the neurosciences.  With dedicated, full-time research personnel and highly-qualified investigators, CINF has developed a strong record of clinical research since 1998. 
Multi-Center Trials

Clinical efficacy of an intra-arterial medication for acute ischemic stroke due to middle cerebral artery occlusion. (PROACT II)

A double-blind, parallel-group, multi-national, multi-center study of the efficacy and safety of an i.v. neuroprotective agent compared to placebo in patients with acute ischemic stroke. (Class-I)

A double-blind, parallel-group, multi-national, multi-center study of safety of an i.v. neuroprotective agent compared to placebo in patients with acute intracerebral hemorrhage. (Class-H)

A double-blind, parallel group, multi-national, multi-center study of safety of an i.v. neuroprotective agent compared to placebo in patients treated with t-PA for acute ischemic stroke. (Class-T)

An international, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess over 3 months the safety, efficacy and pharmacoeconomics of a neuroprotective agent in the treatment of patients with a clinical diagnosis of acute stroke. (GAINS)

A six month post stroke follow-up protocol for subjects who have previously completed clinical trial protocol (An international, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess over 3 months the safety, efficacy and pharmacoeconomics of a neuroprotective agent in the treatment of patients with a clinical diagnosis of acute stroke). (GAINS-SIS)

A randomized, double-blind, placebo-controlled, multi-center study of the effects of an i.v. neuroprotective agent on the amelioration of neurological damage and improvement of stroke assessment scale scores in patients with acute ischemic stroke. (ONO2506)

A randomized, double blind, multi-center study to evaluate the tolerability and effectiveness of a COX2 inhibitor versus NSAIDS in patients with osteoarthritis.

A prospective, randomized, multi-center investigation of the safety and efficacy of RayTFC cervical device.

Research creating a voluntary North American database of outcomes for patients who undergo surgery for glioma. This database will serve as a tool to better understand clinical practices in the care of these patients and the relationship between medical practices and clinical outcomes (GO Project).

A double-blind, placebo controlled, safety, efficacy and dose response trial of three intravenous doses of a neuroprotective agent (maxi-K channel opener) in patients with acute stroke. (POST)

Comparison of autograft to a demineralized bone matrix combined with autograft used in posterolateral lumbar spinal fusion. (DBX)

Phase III randomized multi-center trial of surgical resection, Gliadel Wafer, and irradiation versus surgical resection and irradiation alone for the treatment of operable, solitary brain metastasis from systemic cancer.

Phase II treatment of adults with newly diagnosed primary malignant glioblastoma multiforme with Temodar (chemotherapy agent).

Phase II treatment of adults with progressive or recurrent primary central nervous system lymphoma with Temodar (chemotherapy agent).

A randomized, double-blind, placebo-controlled study of a neuroprotective agent in subjects beginning treatment within 6-hours of the onset of acute, ischemic stroke.

A prospective, randomized, controlled study of an Artificial Cervical Disc vs. Anterior Cervical Fusion at a single level for symptomatic cervical disc disease. Followed by a post-approval study of the device.

A study of Metal Ions in the Continued Access Arm of a clinical trial of an artificial cervical disc at a single level for symptomatic cervical disc disease. Followed by a post-approval study of the device.

A prospective, multicenter, controlled clinical trial of an Artificial Cervical Disc (low-profile) at a single level for symptomatic cervical disc disease. Followed by a post-approval study of the device.

A randomized, controlled clinical study to evaluate the safety and effectiveness of a Synthetic Cortical Bone Void Filler in Vertebral Augmentation.

A phase II study of fractionated CyberKnife stereotactic radiosurgery for high-grade gliomas in elderly patients with poor performance status.

A prospective study comparing two types of synthetic bone graft in patients requiring transforaminal lumbar interbody fusion (TLIF) using an interbody cage implant.

Early operative intervention versus delayed treatment for vertebral body compression fractures: Comparison of clinical and economical outcomes.

Obesity and the Neurosurgical Patient: Investigation into Patients' Perception of Weight.

EVOLVE: A prospective and multicenter evaluation of outcomes for quality of life and activities of daily living for balloon kyphoplasty in the treatment of vertebral compression fractures.


Clinical Outcome Trials

A retrospective study, using ten years of patient data, to investigate whether plates provide a faster fusion rate and/or better functional outcome than non-plate approaches for the treatment of Cervical Disc Disease. Outcome measurements were lessened patient discomfort, faster functional recovery, and cost effectiveness.

A retrospective review of two decompressive lumbar laminectomy techniques: feasibility and safety of the unilateral functional "mini-open" vs. "classic" open approach.
CINF has worked with the following sponsors

Abbott Laboratories
AstraZeneca
GlaxoWellcome
Rhone-Poulenc Rorer
Aventis
Guilford Pharmaceuticals
Bristol-Myer Squibb
Parexel
Schering-Plough Research
Integrated Therapeutics
Duke University
Ohio State University
Pfizer
United States Surgical/Tyco
Synthes Spine
Merck & Co., Inc.
Ono Pharmaceuticals
Omnicare
Stryker Howmedica Osteonics
Medtronic Sofamor Danek
New York University
CTMS
ApaTech, Inc.
NTI Pharmaceuticals


CINF Facilities &
Points of Interest

We are centrally located in Bloomington/Normal, Illinois serving a diverse catchment population of 1.8 million. Our location and services make us accessible to rural communities that otherwise may not have access to current and investigative treatments.

Our 28,000 square foot facilitiy consists of a large neurosurgical medical practice, two neurologiy clinics, diagnostic imaging center, physical therapy/rehabilitation clinic, and two pain management centers.

The Foundation research staff has extensive experience in conducting clinical research. Our staff members take pride in their work, understanding the importance of performing high quality research.

The Foundation works with highly experienced investigators and personnel, dedicated to full-time research. The investigators and research staff are familiar with and strictly adhere to the U.S. FDA Code of Federal Regulations, ICH, and Good Clinical Practice guidelines.

Our organization enjoys participating in  Phase IIA-IV clinical trials. We are experienced in both in-patient and out-patient clinical trials.

The CINF research department is equipped with locked drug/device storage, dedicated monitoring stations with telephone and high-speed internet access.

CINF is affiliated with several area medical centers located throughout Central Illinois. We have developed and continue to maintain very good relationships with local and central Institutional Review Boards.
Celebrating 20 Years of
Enhancing Neuro Healthcare
Through Education and Research